A Seeking Alpha analyst has upheld a Buy rating for Neurocrine Biosciences following the company's acquisition of Soleno [1].
This rating suggests confidence in the company's long-term valuation and its ability to integrate new acquisitions while scaling its existing pharmaceutical portfolio. The move comes as the company seeks to expand its footprint in the neuroscience sector.
The analyst said Neurocrine Biosciences stays a Buy as Ingrezza, Crenessity, and Vykat drive 44% revenue growth [1]. This growth is attributed to the performance of these core products, which the analyst believes provides a stable foundation for the company's valuation, patents, and future catalysts [1].
Market data indicates a positive short-term trend for the company's stock. Neurocrine Biosciences saw a 6.46% increase in its share price over the course of one week [2]. This upward movement reflects broader investor sentiment regarding the company's strategic direction and the specific impact of the Soleno deal.
The acquisition of Soleno is viewed as a key driver for future growth. By combining the potential of the new acquisition with the established revenue streams of its current products, the analyst said the company is well-positioned for continued expansion [1].
Recent market activity suggests that momentum investing may be playing a role in the stock's trajectory. One report said momentum investing is all about the idea of following a stock's recent trend, which can be in either direction [2]. For Neurocrine Biosciences, that trend has remained positive as the company executes its current growth strategy in the U.S. market.
“Neurocrine Biosciences, Inc. stays a Buy as Ingrezza, Crenessity, and Vykat drive 44% revenue growth”
The maintenance of a Buy rating despite the capital expenditure of an acquisition indicates that analysts view the Soleno deal as additive rather than dilutive. By leveraging a 44% growth rate from its established product line, Neurocrine Biosciences is attempting to balance the risk of new acquisitions with the reliability of its current market share in the neuroscience space.
